STEP-HFpEF Program: Semaglutide and NYHA Class in Obesity-Related HFpEF | ADA 2024

Harlan Krumholz, MD, FACC, Editor-in-Chief of JACC and Mikhail Kosiborod, MD, FACC, discuss updates in the STEP-HFpEF trial, particularly for women with obesity. Dr. Kosiborod demonstrated that the drug semaglutide can lead to substantial weight loss and improvements in heart failure-related symptoms and physical limitations. These findings challenge the traditional view of obesity as a mere comorbidity, suggesting it is a key driver of heart failure progression. The results indicate a paradigm shift in cardiovascular health, emphasizing the importance of addressing obesity to effectively manage heart failure.

Expert analysis and key takeaways:
Introduction (00:00)
STEP-HFpEF Trial Background (00:33)
Identifying obesity as a disease (02:48)
What's new & coming out of STEP-HF Program (04:09)
Game changing treatment (04:33)
Weight loss/drug/HF improvement (05:29)
Breakdown of ADA papers (07:24)
NYHA class (07:37)
Outcomes by sex (08:36)
Clinical implications (09:33)
Key messages about weight loss (09:54)
Key messages about NYHA class (10:35)
Key messages about clinical implications (11:31)
Future research studies (12:37)

Related article:
https://www.jacc.org/doi/10.1016/j.ja...

#jacc #jaccjournals #adascisessions